Results With YORVIPATH | YORVIPATH® (palopegteriparatide) Patient Site
Why YORVIPATH

Results With YORVIPATH

YORVIPATH was assessed in a 26-week clinical study

82 adults with hypopara participated in the study
61 adults received YORVIPATH in study versus 21 adults received placebo in study 61 adults received YORVIPATH in study versus 21 adults received placebo in study
Dosing and dose adjustment protocol:
  • All participants were on conventional therapy, then were assigned to take either YORVIPATH or placebo
  • Doses for YORVIPATH, placebo, and conventional therapy were adjusted by a doctor based on blood calcium levels
*The placebo injection was meant to act like the YORVIPATH injection, but without any active substances.

The effectiveness of YORVIPATH was measured by a strict set of treatment criteria

To be considered responsive to treatment with YORVIPATH, people had to meet ALL of the following criteria at Week 26:
  • Normal blood calcium levels
  • Independence from conventional therapy† since Week 22
  • No increase in YORVIPATH or placebo doses since Week 22
  • No missing conventional therapy data since Week 22
  • The YORVIPATH or placebo dose was less than or equal to 30 micrograms per day during the entire study

Nearly 70% of people responded to treatment with YORVIPATH at Week 26‡

68.9-percent-of-adults on YORVIPATH versus 4.8 percent of adults on placebo 68.9-percent-of-adults on YORVIPATH versus 4.8 percent of adults on placebo
Results from individual measurements in the study§:
Treatment effectiveness chart Treatment effectiveness chart
91.8% of people taking YORVIPATH did not take more than 30 mcg daily at any point during the 26-week study. 
†Independence from conventional therapy was defined as no active vitamin D or therapeutic calcium (elemental calcium more than 600 mg per day) with no as-needed doses since Week 22.
‡The goal of treatment with YORVIPATH is to maintain normal blood calcium levels without the need for active vitamin D or calcium (more than 600 mg per day). Calcium supplementation needed to meet daily dietary requirements may be continued.
§At the end of the study, people who responded to treatment with YORVIPATH had reduced their average daily dose of calcium to 600 mg or less (with none taken as needed) and had eliminated their need for daily active vitamin D. An additional measure of effectiveness was that responders to YORVIPATH did not have any missing active vitamin D or calcium data after Week 22 of the study.
YORVIPATH helped the majority of people in the study to maintain normal blood calcium while reducing—or even eliminating—their need for calcium and active vitamin D

YORVIPATH helped to reduce the amount of calcium and active vitamin D people needed daily‖

Reduction in the number of daily active vitamin D and calcium pills in the YORVIPATH study

Before the study:
People took an average of 6.7 pills per day
At Week 26:
People on placebo were still taking an average of 5.4 pills per day
People on YORVIPATH were taking an average of 0.5 pills per day
‖All people in the study were part of this analysis, including those who received YORVIPATH doses of more than 30 mcg/day at any point during the study.
Joanna headshot
“The biggest difference is that I feel like I’m able to more predictably manage my hypoparathyroidism. There aren’t as many ups and downs, and the lows are much less frequent.”
– Joanna, a real YORVIPATH patient

Interested in seeing if YORVIPATH is right for you but don’t know where to begin? Use this tool to find a doctor close to you.

Find a doctor

YORVIPATH Safety

See safety results from the clinical study.

Learn more

Patient Stories

Gain insight into the journeys of people treating their hypopara with YORVIPATH.

Get inspired by people like you

Stay connected

Fill out the form below for important information and resources about YORVIPATH.

*Required Field
*Required Field
*Required Field
*Required Field

Privacy Notice

By checking this box, I certify that I am a resident of the United States and 18 years or older and agree to Ascendis Pharma Terms of Use. I understand and agree that the information I provide will be used in line with the Ascendis Pharma Privacy Policy, including to provide me with marketing information, such as newsletters and updates, and to contact me for my opinion regarding products, programs, and services.

I understand that at any time I may unsubscribe by clicking on the designated link in the material.

Consent

By checking this box, I confirm that I have given my consent to the collection and processing of the information provided as answers marked with *. This information will solely be used to tailor our communications to you. You may at any time withdraw your consent. For more information, please see our Privacy Policy.

IMPORTANT SAFETY INFORMATION AND USE

What is the most important information I should know about YORVIPATH®?

YORVIPATH may cause serious side effects, including:

  • High levels of calcium in the blood (hypercalcemia). YORVIPATH can cause some people to have higher blood calcium levels than normal. Your healthcare provider should check your blood calcium before you start and during your treatment with YORVIPATH. Tell your healthcare provider right away if you have nausea, vomiting...

IMPORTANT SAFETY INFORMATION AND USE

What is YORVIPATH® used for?

YORVIPATH is a prescription medicine used to treat adults with low parathyroid hormone (PTH) (hypoparathyroidism).

  • It is not known if YORVIPATH is safe and effective in people who have been recently diagnosed with hypoparathyroidism after surgery, or if it is started in people with low levels of calcium in the blood.
  • It is not known if YORVIPATH is safe and effective in children.
  • YORVIPATH should not be used in children and young adults whose bones are still growing.

What is the most important information I should know about YORVIPATH?

YORVIPATH may cause serious side effects, including:

  • High levels of calcium in the blood (hypercalcemia). YORVIPATH can cause some people to have higher blood calcium levels than normal. Your healthcare provider should check your blood calcium before you start and during your treatment with YORVIPATH. Tell your healthcare provider right away if you have nausea, vomiting, dizziness, feeling thirsty, confusion, muscle weakness, or irregular heartbeat. Hypercalcemia is more likely to occur within the first 3 months of starting YORVIPATH, but it may occur at any time.
  • Low levels of calcium in the blood (hypocalcemia). People who stop using, miss, or change a dose of YORVIPATH may have an increased risk of low blood calcium levels, but hypocalcemia may occur at any time. Tell your healthcare provider right away if you have tingling in your fingertips, toes, lips or tongue, muscle spasms or cramps, oral numbness, depression, have problems thinking or remembering, abnormal heart rhythms, or seizures.
  • Possible bone cancer (osteosarcoma). Tell your healthcare provider right away if you have pain in any areas of your body that does not go away or any new or unusual lumps or swelling under your skin that is tender to touch. These are some of the signs and symptoms of osteosarcoma and your healthcare provider may need to do further tests.

Who should not take YORVIPATH?

Do not use YORVIPATH if you are allergic to palopegteriparatide or any of the other ingredients in YORVIPATH.

What should I tell my healthcare provider before taking YORVIPATH?

Before using YORVIPATH, tell your healthcare provider about all of your medical conditions, including if you:

  • are at higher risk of a type of bone cancer called osteosarcoma. This is especially important:
    • if you have a bone disease that increases your risk of developing osteosarcoma (including if you have Paget’s disease).
    • if a blood test shows that you have unexplained increases in bone alkaline phosphatase.
    • if you have cancer of the bones or other cancer that has spread to your bones.
    • if you are having or have had radiation therapy to the skeleton.
    • if you are affected with a condition that runs in your family that can increase your chance of getting cancer in your bones.
  • take medicines that contain digoxin, are used to treat osteoporosis, or can affect calcium levels in your blood.
  • are pregnant or plan to become pregnant. It is not known if YORVIPATH will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with YORVIPATH.
  • are breastfeeding or plan to breastfeed. It is not known if YORVIPATH passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with YORVIPATH.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YORVIPATH and other medicines may affect each other causing side effects.

What are the possible side effects of YORVIPATH?

YORVIPATH may cause serious side effects:

  • Allergic (hypersensitivity) reaction, including anaphylaxis. Stop taking YORVIPATH and tell your healthcare provider or get emergency medical help right away if you have swelling of your face, lips, mouth, or tongue, breathing problems, fainting, dizziness, feeling lightheaded (low blood pressure), fast heartbeat, itching, rash, or hives.
  • Decrease in blood pressure when you change positions (orthostatic hypotension). Some people may feel dizzy, get a fast heartbeat, or feel light-headed right after injecting YORVIPATH. For the first few doses, give your injection of YORVIPATH in a place where you can sit or lie down right away if you get these symptoms. If your symptoms get worse or do not go away, contact your healthcare provider before you continue using YORVIPATH.
  • Digoxin toxicity if you are using digoxin and YORVIPATH at the same time. Tell your healthcare provider if you experience irregular heart rhythm, heart palpitations, confusion, loss of appetite, nausea, vomiting, diarrhea, or vision problems.

The most common side effects of YORVIPATH include injection site reactions, vasodilatory signs or symptoms such as a drop in blood pressure or lightheadedness when standing up, headache, diarrhea, back pain, high calcium levels, and sore throat.

These are not all of the possible side effects of YORVIPATH. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Please click here for full Prescribing Information for YORVIPATH, including the Medication Guide.

Hypopara=hypoparathyroidism; PTH=parathyroid hormone.

This site is for US residents only.

Please confirm you are a US resident.

Cancel

You are about to leave the Yorvipath.com website by opening a new webpage.

The site you are linking to is not controlled or endorsed by Ascendis Pharma and we are not responsible for the content presented on that site.

Thank you for visiting Yorvipath.com.

Confirm